ATN-161 trifluoroacetate salt is a novel integrin α5β1 antagonist that inhibits angiogenesis in a mouse model of liver metastasis; it significantly reduces tumor cell proliferation when combined with 5-FU compared to control or monotherapy (p<0.01); the combination therapy also significantly increases apoptotic (TUNEL-positive) tumor cells (p<0.03), whereas monotherapy does not; ATN-161 treatment leads to a significant reduction in endothelial cell (EC) number (21% decrease) after 48 hours of incubation compared to control (p<0.03); it inhibits VEGF-induced migration and capillary tube formation in human coronary endothelial cells (hCECs) without affecting proliferation; ATN-161 decreases VEGF-induced cell migration in a dose-dependent manner starting at 100 nM (P<0.001 vs. VEGF group); in vivo, ATN-161 significantly reduces tumor weight and vessel density in α5β1-negative human colon cancer xenografts (HT29); intravitreal injection of ATN-161 after laser photocoagulation inhibits choroidal neovascularization (CNV) leakage and neovascularization to an extent comparable to AF564.